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Poor clinical outcomes associated with
suboptimal antibiotic treatment among
older long-term care facility residents with
urinary tract infection: a retrospective
cohort study
Haley J. Appaneal1,2,3,4*, Theresa I. Shireman4, Vrishali V. Lopes1, Vincent Mor2,4, David M. Dosa1,2,3,4,
Kerry L. LaPlante1,2,3,5 and Aisling R. Caffrey1,2,3,4

Abstract
Background: Antibiotic use is associated with several antibiotic-related harms in vulnerable, older long-term care
(LTC) residents. Suboptimal antibiotic use may also be associated with harms but has not yet been investigated.
The aim of this work was to compare rates of poor clinical outcomes among LTC residents with UTI receiving
suboptimal versus optimal antibiotic treatment.
Methods: We conducted a retrospective cohort study among residents with an incident urinary tract infection (UTI)
treated in Veterans Affairs LTC units (2013–2018). Potentially suboptimal antibiotic treatment was defined as use of
a suboptimal initial antibiotic drug choice, dose frequency, and/or excessive treatment duration. The primary
outcome was time to a composite measure of poor clinical outcome, defined as UTI recurrence, acute care
hospitalization/emergency department visit, adverse drug event, Clostridioides difficile infection (CDI), or death within
30 days of antibiotic discontinuation. Shared frailty Cox proportional hazard regression models were used to
compare the time-to-event between suboptimal and optimal treatment.
Results: Among 19,701 LTC residents with an incident UTI, 64.6% received potentially suboptimal antibiotic
treatment and 35.4% experienced a poor clinical outcome. In adjusted analyses, potentially suboptimal antibiotic
treatment was associated with a small increased hazard of poor clinical outcome (aHR 1.06, 95% CI 1.01–1.11) as
compared with optimal treatment, driven by an increased hazard of CDI (aHR 1.94, 95% CI 1.54–2.44).
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Conclusion: In this national cohort study, suboptimal antibiotic treatment was associated with a 6% increased risk
of the composite measure of poor clinical outcomes, in particular, a 94% increased risk of CDI. Beyond the decision
to use antibiotics, clinicians should also consider the potential harms of suboptimal treatment choices with regards
to drug type, dose frequency, and duration used.
Keywords: Urinary tract infection, Suboptimal antibiotic treatment, Veterans affairs, Community living center

Background
Antibiotic resistance poses one of the most urgent and
widespread threats to public health and is driven by antibiotic use [1, 2]. Antibiotics use is highly prevalent in
long-term care facilities (LTCFs) [3]. Antibiotics are
used frequently in older residents for many reasons, including higher risk of infection due to immunosuppression, malnutrition, dehydration, presence of multiple
comorbidities, and functional impairment [4–7]. Several
other issues such as diagnostic uncertainty, the atypical
and/or subtle presentation of common infections, and
the frequency of colonization with antibiotic-resistant
pathogens also contribute to antibiotic use in this population [5]. Approximately 10% of residents are on at least
one antibiotic at any one time and between 50 and 75%
of residents receive an antibiotic over the course of a
year [8–11]. Up to 75% of antibiotic treatment in LTCFs
may be inappropriate, putting already vulnerable residents at risk for unintended consequences of antibiotic
use, including selection for colonization or infection with
resistant organisms and Clostridioides difficile, antibiotic
allergies, and other adverse drug effects and drug toxicities [12–14].
The most common driver of antibiotic use and reason
for inappropriate antibiotic use in LTCFs is urinary tract
infection (UTI) [15]. A study which included one-day
point prevalence surveys from nine nursing homes in four
states demonstrated that one in three antibiotics given to
residents are for UTI and at least half of these antibiotics
are inappropriate with regards to the drug choice, dose, or
duration given [16]. Other studies have estimated that between 25 and 85% of antibiotic prescriptions for residents
with UTIs are inappropriate [17–20].
Prior studies have assessed the harms associated with
unnecessary antibiotic use [18, 21, 22]. No previous
studies have assessed the harms associated with suboptimal antibiotic use, whether or not the antibiotics were
necessary or unnecessary. Suboptimal antibiotic treatment as assessed by drug choice, dose, and/or duration,
in already frail, older residents could also be associated
with other poor clinical outcomes such as infection recurrence, acute care hospitalizations, visits to the emergency department, or even mortality [23, 24]. The aims
of this study were to compare rates of poor clinical outcomes among LTCF residents with UTI receiving suboptimal and optimal antibiotic treatment. Our study

focused on suboptimal antibiotic treatment, which has
previously been defined as use of antibiotics in the setting of established infection that can be improved [25].
In clinical practice, the antibiotic-decision making
process is complex and many factors need to be considered to ensure that optimal therapy is used [12, 26].
Therefore, we sought to assess the clinical impact of several domains of suboptimal antibiotic treatment, including the drug choice, dose frequency, and/or duration of
therapy, all of which have the potential to be improved
should a negative clinical impact be observed.

Methods
The study design and methods were defined a priori in
the study protocol, which was approved by the Institutional Review Board (IRB) and the Research and Development (R&D) Committee of the Providence Veterans
Affairs Medical Center prior to initiation with a waiver
of the informed consent process. All methods were carried out in accordance with relevant guidelines and
regulations.
Data sources, study design, setting, and population

We used data from the national VA Corporate Data
Warehouse including microbiology reports, inpatient and
outpatient care, diagnoses, procedures, surgeries, demographics, vital status, inpatient and outpatient medications, laboratory, and vital measurements. We conducted
a retrospective cohort study of residents with a suspected
incident UTI (first during the study with none in the year
prior) treated in VA long-term care units (known as community living centers or CLCs) from January 2013 to December 2018. We included residents with incident CLC
UTIs, however they could have had a UTI in another setting (e.g. hospital or outpatient) previously. Figure 1 presents a flow chart of methods used to identify our study
population [27, 28]. Suspected UTIs required the collection of a urine culture (despite whether or not the culture
was ultimately positive or negative for microbial growth)
and an antibiotic given on the culture collection date or
within 3 days after culture collection [27, 28]. We excluded residents with a recent urologic procedure, female
residents of childbearing age, those treated with antibiotics
for over 30 days, those with other positive cultures, and
those treated with any non-UTI or uncommon antibiotics.
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Fig. 1 Flow chart for study population. CLC = Community Living Center, ICD-9/ICD-10 = International Classification of Diseases, 9th or 10th
Revision diagnosis codes, UTI = Urinary tract infection; VA = Veterans Affairs. Figure adapted from previously published work [27].

We also excluded residents who were treated with antibiotics for 2 days or less.
Exposure

We compared residents with UTIs receiving potentially
suboptimal antibiotic treatment with those receiving potentially optimal antibiotic treatment. Potentially suboptimal antibiotic treatment was defined as use of a
suboptimal initial antibiotic drug choice, dose frequency,
and/or excessive treatment duration [27]. Initial drug
choice was considered suboptimal based on resistance to
the antibiotics used on day 1 of treatment, considering

the resident’s urine culture and susceptibility results in
the previous 180 days. If no urine culture and susceptibility data were available, the initial agents used were
considered suboptimal if they provided insufficient
coverage (susceptibility < 80% based on the CLC urine
antibiogram for the year prior). Dose frequency was considered suboptimal based on renal function. In the case
of missing serum creatine, dose frequency was defined
as suboptimal, as clinicians would be unable to perform
renal dose adjustment without an estimate of creatine
clearance. Antibiotic duration was considered excessive
if was ≥ 14 days.
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Outcomes

The primary outcome of interest was time to a composite measure of any of the following poor clinical outcomes within 30 days of antibiotic discontinuation: UTI
recurrence, acute care hospitalization or emergency department (ED) visit, adverse drug event, Clostridioides
difficile infection (CDI), or death. For residents who experienced more than one of these poor clinical outcomes
of interest we considered the event that occurred first.
For secondary outcomes, we assessed time to each poor
clinical outcome separately. We censored residents who
were alive and without the event of interest after 30 days.
Table 1 presents study definitions used for primary and
secondary outcomes.
Analytic approach

We compared the composite measure of poor clinical
outcomes, as well as the individual clinical outcomes,
among residents with incident UTIs receiving potentially
suboptimal and optimal antibiotic treatment. Differences
between groups were analyzed using chi-square for categorical data and Student’s t test or the Wilcoxon rank
sum test for continuous data, as appropriate. To account
for the multi-level structure of our data (individual residents with UTIs clustered within CLCs), CLC was included a random effect in our models with log-normal
distribution to represent shared frailty among residents
of the same CLC [33]. Cox models with mixed effects
were used to compare the primary (time to composite
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poor clinical outcome) and secondary outcomes (time to
each individual clinical outcome) between groups and to
estimate crude and adjusted hazard ratios (aHRs) and
95% confidence intervals (CI) [33]. The adjusted multivariable models included resident-level predictors of
suboptimal antibiotic treatment and that were also associated with the poor clinical outcomes [27]. We also adjusted for CLC-level variables predictive of suboptimal
antibiotic treatment [34]. All predictors included in the
adjusted analyses are presented in the results tables.
Evaluation of assumptions and plotting of relevant
model parameters were conducted, including for the assessment of proportionality [35].
We conducted subgroup analyses among residents
who were initially treated with only one antibiotic class
(fluroquinolones, cephalosporins, genitourinary tact
agents, or other beta lactams). We also conducted subgroup analyses among residents who received only one
subtype of suboptimal treatment (drug choice, dose frequency, or excessive treatment duration). Finally, we
conducted sensitivity analyses with varying follow-up
times (14, 60, 90, 180 days). We used a shorter 14-day
follow-up time as some events such as UTI recurrence,
acute care hospitalization or emergency department
visits, and adverse drug events, tend to occur during or
shortly after exposure to antibiotics [21, 36]. Other
events, such as CDI, can occur several weeks to months
after discontinuing antibiotic therapy. We used longer
follow-up times (up 60, 90, and 180 days) to capture

Table 1 Study definitions used to measure composite and individual poor clinical outcomes
Outcome

Definition

Methods

Primary outcome (composite outcome)
Poor clinical outcome

UTI recurrence, acute care hospitalization or ED visit,
adverse drug event, CDI, or death

Each individual clinical outcome defined as below.

Secondary outcomes (individual poor clinical outcomes)
UTI recurrence

Subsequent UTI after the first incident UTI

UTI recurrences were identified using the same methods
to identify the first incident UTI.
Required urine culture collection and an antibiotic given
on the culture collection date or within 3 days after culture
collection.

Acute care hospitalization
or ED visit

Any admission to an acute care unit or ED within
30 days of end of antibiotic treatment, except for
those for an elective hip or knee procedure

VA hospitalizations were captured using VA inpatient
admission data.
VA ED visits were captured using VA outpatient visit data.
Non-VA hospitalizations and ED visits VA Fee basis files
were captured using VA Fee basis files.
ICD-9 or 10 procedure codes were used to identify elective
hip or knee procedures (see supplement for codes).

Antibiotic related adverse
drug events

Diagnosis of an antibiotic related adverse drug event

Previously published ICD-9 or 10 lists were used to identify
antibiotic related adverse drug events (see supplement for
codes) [29, 30].

CDI

Laboratory evidence of CDI or diagnosis of CDI

Positive stool sample for C. difficile toxin(s) or ICD-9 or
10 diagnosis code for CDI (008.45, A04.71, A04.72) [31, 32].

All-cause mortality

Death due to any cause

The Vital Status Mini File was used to confirm date of death.

CDI Clostridioides difficile infection, ED Emergency Department, ICD-9 or 10 International Classification of Diseases, Ninth and Tenth Edition, Clinical Modification,
UTI Urinary tract infection
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events that might develop beyond 30 days after antibiotic
discontinuation (available in supplemental material) [37].
We used SAS (version 9.2) and R-studio (version 3.6.1)
for our analyses.

Results
From 2013 to 2018, we identified 19,701 CLC residents
with an incident UTI treated in 120 VA CLCs treated
for at least 3 days. Overall, 64.6% of residents (n =
12,718) received potentially suboptimal antibiotic treatment and 35.4% (n = 6983) received potentially optimal
antibiotic treatment. The CLC at the median used potentially suboptimal antibiotic treatment in 66.3% of residents with an incident UTI (range from 36.8% for the
CLC with the lowest suboptimal use to 100% for the
CLC with the highest suboptimal use).
As expected, there were several differences in the baseline characteristics and initial (empiric) antibiotic treatment of residents receiving potentially suboptimal versus
optimal antibiotic treatment (Table 2). Those receiving
potentially optimal antibiotic treatment were more likely
to have chronic renal disease (29.7% vs. 27.3%, p < 0.001)
and exposure to any antibiotic in the last 30 days (44.4%
vs. 42.0%), and less likely to have a UTI diagnosis in the
year prior (34.3% vs. 40.3%), compared with those receiving optimal antibiotic treatment.
Overall, 37.2% (n = 7337) of residents with an incident
UTI experienced a poor clinical outcome within 30 days
of antibiotic discontinuation (Table 2). Time to event
analyses comparing residents who received potentially
suboptimal antibiotic treatment to those who received
optimal antibiotic treatment are presented in Table 3.
The median time to the first of any of the composite
poor clinical outcomes was 10 days (IQR 4–18.5) in residents receiving potentially suboptimal antibiotic treatment and 11 days (IQR 5–19) in those receiving optimal
antibiotic treatment, p = 0.001. In adjusted analyses, receipt of potentially suboptimal antibiotic treatment was
associated with a small increased hazard of the composite poor clinical outcome (aHR 1.06, 95% CI 1.01–1.11)
as compared with optimal antibiotic treatment. Receipt
of potentially suboptimal antibiotic treatment was associated with an increased hazard of CDI (aHR 1.94, 95%
CI 1.54–2.44), but not with any other individual clinical
outcome assessed.
Results of subgroup analyses among those who initially
received only one antibiotic class can be found in
Table 4. Potentially suboptimal treatment was not associated with an increased hazard of the composite poor
clinical outcome in any of the subgroups of residents
who were initially treated with one class of antibiotics
alone (fluroquinolones, cephalosporins, genitourinary
tact agents, or other beta lactams). However, among
those initially treated with fluoroquinolones alone (aHR
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1.91, 95% CI1.09–3.36) and among those who initially
received cephalosporins alone (aHR 1.93, 95% CI 1.12–
3.31), potentially suboptimal treatment was associated
with an increased hazard of CDI.
Results among those who received only one subtype of
suboptimal treatment (suboptimal drug choice, dose frequency, or longer than recommended duration) as compared with optimal treatment can be found in Table 5.
In adjusted analyses, receipt of suboptimal dose frequency was associated with an increased hazard of the
composite poor clinical outcome (aHR 1.29, 95% CI
1.20–1.39). Suboptimal drug choice and longer than recommended treatment duration were not associated with
the composite poor clinical outcome. Suboptimal dose
frequency was associated with an increased hazard of
hospitalization/ED visit (aHR 1.13, 95% CI 1.02–1.26),
all-cause mortality (aHR 1.44, 95% CI 1.26–1.65), and
CDI (aHR 3.21, 95% CI 2.42–4.25). Longer than recommended treatment duration was associated with a decreased hazard of mortality (aHR 0.71, 95% CI 0.55–
0.90).
In sensitivity analyses, potentially suboptimal antibiotic
treatment was associated with an increased hazard of
the composite poor clinical outcome using a shorter
follow-up of 14 days, but was not with a longer followup of 60, 90, or 180-days (see Supplementary Table 1).
Potentially suboptimal antibiotic treatment was not associated with an alternate definition of the composite poor
clinical outcome which excluded CDI, except in the
shortest follow-up period of 14 days (see Supplementary
Table 2).

Discussion
To our knowledge, this study is the first to focus specifically on comparing rates of poor clinical outcomes
among residents with UTI based on suboptimal versus
optimal antibiotic treatment. This work suggests an association between suboptimal antibiotic treatment and
poor clinical outcomes driven by a 94% increased risk of
CDI. Our study is the first to identify an increased risk
of CDI among residents with UTI who did not receive
an optimal antibiotic, and/or dose frequency, and/or
duration, despite whether the treatment was necessary
or unnecessary.
Our work advances previous work indicating antibiotic
use is associated with a number of unintended harms in
LTCF residents [18, 38, 39]. Among 110,656 older adults
residing in 607 nursing homes in Canada, residence
alone in nursing homes with high antibiotic use was associated with an increased risk of residents experiencing
an antibiotic-related adverse event (adjusted odds ratio,
1.24; 95% CI, 1.07–1.42; p = 0.003) [39]. Work in other
settings has similarly confirmed that antibiotic-related
harms are common. In the hospital setting, it is
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Table 2 Baseline characteristics, initial antibiotics and outcomes among residents with urinary tract infections receiving potentially
suboptimal and optimal antibiotic treatment
Potentially suboptimal
antibiotic treatment
(n = 12,718)

Potentially optimal
antibiotic treatment
(n = 6983)

P value

Age in years, median (IQR)

75 (67–85)

74 (67–84)

p < 0.001

Male gender

12,208 (96)

6698 (95.9)

0.808

White race

9477 (74.5)

5266 (75.4)

0.166

Chronic renal disease comorbidity

3783 (29.7)

1905 (27.3)

< 0.001

Cardiopulmonary disease comorbidity

9156 (72)

5158 (73.9)

0.005

Genitourinary disease comorbidity

6733 (52.9)

3833 (54.9)

0.009

Urinary tract infection diagnosis in the year prior

4357 (34.3)

2815 (40.3)

< 0.001

Skin or soft tissue infection diagnosis in the year prior

2631 (20.7)

1266 (18.1)

< 0.001

Hospitalization, 30 days prior treatment

3708 (29.2)

2127 (30.5)

0.06

Exposure to any antibiotic, 30 days prior to treatment

5650 (44.4)

2932 (42.0)

0.001

Exposure to fluoroquinolone, 30 days prior to treatment

1840 (14.5)

776 (11.1)

< 0.001

Fluoroquinolone

5403 (42.5)

1874 (26.8)

< 0.001

Ciprofloxacin

3972 (31.2)

1585 (22.7)

< 0.001

Levofloxacin

1458 (11.5)

292 (4.2)

< 0.001

Cephalosporin

3160 (24.8)

2274 (32.6)

< 0.001

Cephalexin

1076 (8.5)

287 (4.1)

< 0.001

Ceftriaxone

656 (5.2)

972 (13.9)

< 0.001

2848 (22.4)

1356 (19.4)

< 0.001

Sulfamethoxazole/trimethoprim

2330 (18.3)

1070 (15.3)

< 0.001

Nitrofurantoin

510 (4)

273 (3.9)

0.366
< 0.001

Baseline Characteristics

Initial Antibiotic Treatment

Typical genitourinary tract agent

Other beta lactam

2394 (18.8)

1575 (22.6)

Amoxicillin/clavulanate

1101 (8.7)

425 (6.1)

< 0.001

Piperacillin/tazobactam

687 (5.4)

579 (8.3)

< 0.001

Amoxicillin

487 (3.8)

328 (4.7)

0.003

Other antibiotics

1134 (8.9)

821 (11.8)

< 0.001

Vancomycin

975 (7.7)

711 (10.2)

< 0.001

Clindamycin

33 (0.3)

<5

0.001

9 (7–12)

8 (6–10)

p < 0.001

0.179

Treatment duration in days, median (interquartile range)
Outcomesa
Poor clinical outcome

4780 (37.6)

2557 (36.6)

Hospitalization/ Emergency department visit

2499 (19.6)

1386 (19.8)

0.737

UTI recurrence

1589 (12.5)

927 (13.3)

0.116

All-cause mortality

1418 (11.1)

703 (10.1)

0.019

Clostridioides difficile infection

339 (2.7)

98 (1.4)

< 0.001

Antibiotic related adverse drug event

27 (0.2)

17 (0.2)

0.658

CLC Community Living Center, UTI Urinary tract infection
Data are presented as n (%), unless otherwise specified
a
Crude outcome rates at 30 days
We compared baseline characteristics, initial antibiotic treatment (day 1, empiric treatment) and outcomes among CLC residents with an incident UTI receiving
potentially suboptimal antibiotic treatment and those receiving potentially optimal antibiotic treatment. We present a few significant differences in baseline
characteristics in the Table above. Our previous work compares baseline characteristics (including socio-demographics, comorbidities, prior healthcare exposures,
prior infections, prior antibiotic exposures, prior culture collection, and prior laboratory results) between groups in more detail [27].
Potentially suboptimal antibiotic treatment was defined as exposure to any subtype of potentially suboptimal antibiotic treatment: drug choice (based on
previous urine cultures and susceptibilities or local CLC urine antibiogram), dose frequency (based on renal function), and/or longer than recommended duration
(greater than 14 days)
The following agents were included in each class: fluoroquinolones (ciprofloxacin, levofloxacin), typical genitourinary tract agents (nitrofurantoin,
sulfamethoxazole/ trimethoprim, fosfomycin, trimethoprim), cephalosporins (cefaclor, cefazolin, cefotetan, cefoxitin, cefuroxime, cephalexin, cefdinir, cefepime,
cefixime, cefotaxime, cefpodoxime, ceftazidime, ceftriaxone), and other beta-lactams (amoxicillin, ampicillin, amoxicillin/clavulanate, amipicillin/sulbactam,
imipenem, meropenem, ertapenem, doripenem, piperacillin/ tazobactam)

(2021) 21:436
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Table 3 Time to event analyses among CLC residents with UTI receiving potentially suboptimal and optimal antibiotic treatment

Poor clinical outcomea

Median time in days to event for
residents who received potentially
suboptimal treatment
(n = 12,718)

Median time in days to event for
residents who received potentially
optimal treatment
(n = 6983)

Unadjusted HR
(95% CI)

Adjusted HR
(95% CI)

10 (4–18.5)

11 (5–19)

1.05 (1.00–1.10)

1.06 (1.01–1.11)

Hospitalization/ Emergency
department visitb

11 (4–20)

12 (5–20)

0.99 (0.93–1.06)

1.02 (0.96–1.10)

UTI recurrencec

13 (7–21)

14 (8–21)

0.93 (0.86–1.01)

0.97 (0.89–1.05)

All-cause mortalityd

9 (3–18)

9 (3–18)

1.11 (1.02–1.22)

1.05 (0.95–1.15)

e

Clostridioides difficile infection

10 (3–17)

11 (5–17)

2.03 (1.62–2.54)

1.94 (1.54–2.44)

Antibiotic related adverse
drug eventf

6 (1–15)

11 (3–18)

0.89 (0.48–1.64)

0.93 (0.51–1.72)

CI Confidence interval, CLC Community Living Center, HR Hazard ratio, UTI Urinary tract infection, VAMC Veterans Affairs Medical Center
All covariates were included as dichotomous variables representing presence as compared to absence of the characteristic of interest, unless otherwise noted.
Age was included as a categorical variable (≥ 85, 75–84, 65–74 years) as compared to < 65 years. Recent high WBC was included as a WBC > 10 × 103/μL within 7
days prior to treatment as compared to a measurement below or missing. Total CLC incident UTI rate per 10,000 bed days was included as a continuous variable.
Year of episode was included as a discrete variable for each year
a
Adjusted for 8 resident-level covariates (genitourinary disease comorbidity, cardiopulmonary comorbidity, chronic renal disease comorbidity, previous
fluroquinolone exposure in the past 30 days, age, previous VAMC hospitalization in the past 30 days, previous VAMC urine culture in the past 365 days, high white
blood cell count), and 1 CLC-level covariate (total CLC incident UTI rate per 10,000 bed days)
b
Adjusted for 10 resident-level covariates (cardiopulmonary comorbidity, genitourinary disease comorbidity, chronic renal disease comorbidity, age, previous
VAMC hospitalization in the past 30 days, previous outpatient VA urine culture in the past 365 days, previous CLC urine culture in the past 365 days, previous
VAMC urine culture in the past 365 days, high white blood cell count, year of episode) and 1 CLC-level covariate (total CLC incident UTI rate per 10,000 bed days)
c
Adjusted for 5 resident-level covariates (genitourinary disease comorbidity, previous fluroquinolone exposure in the past 30 days, previous fluroquinolone
resistant culture in the past 365 days, previous CLC urine culture in the past 365 days, previous VAMC urine culture in the past 365 days), and 1 CLC-level covariate
(total CLC incident UTI rate per 10,000 bed days)
d
Adjusted for 10 resident-level covariates (history of a skin infection diagnosis in the past 365 days, history of a urinary tract infection diagnosis in the past 365
days, chronic renal disease comorbidity, age, previous fluroquinolone exposure in the past 30 days, previous VAMC hospitalization in the past 30 days, previous
outpatient VA urine culture in the past 365 days, previous VAMC urine culture in the past 365 days, high white blood cell count, year of episode), and 1 CLC-level
covariate (total CLC incident UTI rate per 10,000 bed days)
e
Adjusted for 8 resident-level covariates (history of a skin infection diagnosis in the past 365 days, genitourinary disease comorbidity, chronic renal disease
comorbidity, previous VAMC hospitalization in the past 30 days, previous CLC urine culture in the past 365 days, previous VAMC urine culture in the past 365 days,
high white blood cell count, year of episode), and 1 CLC-level covariate (total CLC incident UTI rate per 10,000 bed days)
f
Adjusted for 2 resident-level covariates (VAMC hospitalization in the past 30 days, year of episode), and 1 CLC-level covariate (total CLC incident UTI rate per
10,000 bed days)
All covariates were included in adjusted models as dichotomous variables representing presence as compared to absence of the characteristic of interest, unless
otherwise noted. Age was included as a categorical variable (≥ 85, 75–84, 65–74 years) as compared to < 65 years. Recent high WBC was included as a WBC > 10 ×
103/μL within 7 days prior to treatment as compared to a measurement below or missing. Total CLC incident UTI rate per 10,000 bed days was included as a
continuous variable. Year of episode was included as a discrete variable for each year

estimated that about 20% of admitted patients treated
with antibiotics develop antibiotic-associated adverse
events, including CDI, development of resistant infections, and other gastrointestinal, cardiac, renal, hepatobiliary, neurologic, dermatologic, and musculoskeletal
adverse manifestations [21, 40, 41]. In the outpatient setting, it is well established that antibiotics are among the
most common cause of adverse drug events [42–44].
Antibiotics are associated with up to 20% of all ED visits
for drug-related adverse events among adults in the
United States [41, 43]. In our study, 37% of residents
treated with antibiotics for incident UTI experienced a
poor clinical outcome.
Our work also corresponds with existing research on
unnecessary antibiotic treatment and associated harms,
including CDI, acquisition of drug-resistant pathogens,
and other adverse events [22, 45, 46]. In a retrospective
study of 172 residents with suspected UTI from two
Rhode Island nursing homes, residents who received antibiotics but did not meet criteria for treatment were 8.5
times (95% CI, 1.7–42.2) more likely to develop CDI

than the rest of the nursing home population [18]. This
is also observed in the hospital setting [22, 47]. While
these previous studies demonstrate an association between unnecessary antibiotic use and the development
of avoidable adverse events, our work advances these
findings, demonstrating an association between suboptimal antibiotic treatment and the development of poor
outcomes. In contrast to previous studies which have
assessed unnecessary treatment, our study assessed residents who did not receive the preferred antibiotic, and/
or dose frequency, and/or duration regardless of treatment necessity.
Our results were largely driven by an increased risk of
CDI associated with suboptimal antibiotic treatment
among residents with UTI. The risk of CDI was 1.94
times higher among residents who received potentially
suboptimal antibiotic treatment as compared to those
who received optimal antibiotic treatment. It is wellknown that antibiotic use is one of the most important
risk factors for CDI, and that any antibiotic exposure
can lead to disruption of the normal gastrointestinal
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Table 4 Time to event analyses among CLC residents who initially received only one antibiotic class
Outcome

Initial Antibiotic
Treatment

Potentially suboptimal Potentially optimal Unadjusted HR Adjusted HR
treatment [n events/n treatment [n events/ (95% CI)
(95% CI)
total, (%)]
n total, (%)]

Poor clinical outcomea

Fluroquinolone

1581/4460 (35.4%)

588/1672 (35.2%)

1.03 (0.94–1.14)

1.05 (0.95–1.16)

Cephalosporin

722/1882 (38.4%)

661/1854 (35.7%)

1.07 (0.96–1.20)

1.06 (0.95–1.18)

Genitourinary tract agent 809/2384 (33.9%)

415/1280 (32.4%)

1.06 (0.94–1.20)

1.09 (0.96–1.23)

Hospitalization/ Emergency
department visitb

UTI recurrencec

All-cause mortalityd

Other beta lactam

599/1578 (38.0%)

432/1087 (39.7%)

0.97 (0.85–1.09)

1.00 (0.88–1.13)

Fluroquinolone

771/4460(17.3%)

312/1672 (18.7%)

0.95 (0.83–1.09)

1.01 (0.88–1.16)

Cephalosporin

406/1882(21.6%)

346/1854(18.7%)

1.08 (0.93–1.26)

1.09 (0.94–1.27)

Genitourinary tract agent 386/2384(16.2%)

217/1280(17.0%)

0.97 (0.82–1.14)

0.96 (0.81–1.15)

Other beta lactam

346/1578(21.9%)

243/1087(22.4%)

1.01 (0.86–1.20)

1.11 (0.94–1.32)

Fluroquinolone

522/4460(11.7%)

201/1672(12.0%)

0.97 (0.82–1.14)

1.00 (0.84–1.19)

Cephalosporin

252/1882(13.4%)

251/1854(13.5%)

0.95 (0.80–1.14)

0.95 (0.79–1.14)

Genitourinary tract agent 372/2384(15.6%)

169/1280(13.2%)

1.04 (0.86–1.25)

1.06 (0.87–1.30)

Other beta lactam

180/1578(11.4%)

177/1087(16.3%)

0.69 (0.56–0.85)

0.78 (0.63–0.97)

Fluroquinolone

527/4460(11.8%)

173/1672(10.3%)

1.16 (0.98–1.38)

1.07 (0.89–1.28)

Cephalosporin

197/1882(10.5%)

182/1854(9.8%)

1.09 (0.88–1.33)

1.06 (0.86–1.30)

93/1280(7.3%)

1.29 (1.01–1.64)

1.26 (0.98–1.63)

Genitourinary tract agent 228/2384(9.6%)
Clostridioides difficile infectione

Other beta lactam

187/1578(11.9%)

108/1087(9.9%)

1.19 (0.94–1.51)

1.15 (0.89–1.48)

Fluroquinolone

66/4460(1.5%)

16/1672(1.0%)

1.56 (0.90–2.71)

1.91 (1.09–3.36)

Cephalosporin

41/1882(2.2%)

20/1854(1.1%)

1.99 (1.16–3.43)

1.93 (1.12–3.31)

Genitourinary tract agent 25/2384(1.0%)

12/1280(0.9%)

1.14 (0.57–2.28)

1.14 (0.55–2.35)

Other beta lactam
Antibiotic related adverse drug eventf Fluroquinolone
Cephalosporin

24/1578(1.5%)

15/1087(1.4%)

1.10 (0.58–2.10)

1.35 (0.69–2.65)

< 0.5%

< 0.5%

0.87 (0.23–3.38)

1.02 (0.26–3.97)

< 0.5%

< 0.5%

1.14 (0.28–4.68)

1.19 (0.29–4.95)

Genitourinary tract agent < 0.5%

< 0.5%

1.10 (0.20–6.03)

1.13 (0.21–6.18)

Other beta lactam

< 0.5%

1.15 (0.27–4.81)

1.14 (0.27–4.75)

< 0.5%

CI Confidence interval, CLC Community Living Center, HR Hazard ratio, UTI Urinary tract infection, VAMC Veterans Affairs Medical Center
a
Adjusted for 8 resident-level covariates (genitourinary disease comorbidity, cardiopulmonary comorbidity, chronic renal disease comorbidity, previous
fluroquinolone exposure in the past 30 days, age, previous VAMC hospitalization in the past 30 days, previous VAMC urine culture in the past 365 days, high white
blood cell count), and 1 CLC-level covariate (total CLC incident UTI rate per 10,000 bed days)
b
Adjusted for 10 resident-level covariates (cardiopulmonary comorbidity, genitourinary disease comorbidity, chronic renal disease comorbidity, age, previous
VAMC hospitalization in the past 30 days, previous outpatient VA urine culture in the past 365 days, previous CLC urine culture in the past 365 days, previous
VAMC urine culture in the past 365 days, high white blood cell count, year of episode) and 1 CLC-level covariate (total CLC incident UTI rate per 10,000 bed days)
c
Adjusted for 5 resident-level covariates (genitourinary disease comorbidity, previous fluroquinolone exposure in the past 30 days, previous fluroquinolone
resistant culture in the past 365 days, previous CLC urine culture in the past 365 days, previous VAMC urine culture in the past 365 days), and 1 CLC-level covariate
(total CLC incident UTI rate per 10,000 bed days)
d
Adjusted for 10 resident-level covariates (history of a skin infection diagnosis in the past 365 days, history of a urinary tract infection diagnosis in the past 365
days, chronic renal disease comorbidity, age, previous fluroquinolone exposure in the past 30 days, previous VAMC hospitalization in the past 30 days, previous
outpatient VA urine culture in the past 365 days, previous VAMC urine culture in the past 365 days, high white blood cell count, year of episode), and 1 CLC-level
covariate (total CLC incident UTI rate per 10,000 bed days)
e
Adjusted for 8 resident-level covariates (history of a skin infection diagnosis in the past 365 days, genitourinary disease comorbidity, chronic renal disease
comorbidity, previous VAMC hospitalization in the past 30 days, previous CLC urine culture in the past 365 days, previous VAMC urine culture in the past 365 days,
high white blood cell count, year of episode), and 1 CLC-level covariate (total CLC incident UTI rate per 10,000 bed days)
f
Adjusted for 2 resident-level covariates (VAMC hospitalization in the past 30 days, year of episode), and 1 CLC-level covariate (total CLC incident UTI rate per
10,000 bed days)
All covariates were included in adjusted models as dichotomous variables representing presence as compared to absence of the characteristic of interest, unless
otherwise noted. Age was included as a categorical variable (≥ 85, 75–84, 65–74 years) as compared to < 65 years. Recent high WBC was included as a WBC > 10 ×
103/μL within 7 days prior to treatment as compared to a measurement below or missing. Total CLC incident UTI rate per 10,000 bed days was included as a
continuous variable. Year of episode was included as a discrete variable for each year

microbiota and result in CDI. Prior work among nursing
home residents, demonstrated that a 7-day antibiotic
course, compared with no antibiotic treatment, was associated with a 1.8 times increased risk of CDI [48]. This
prior work also demonstrated that the risk of CDI varies

by antibiotic agent/class and duration of treatment [48].
Previous work has demonstrated broad-spectrum antibiotics, such as clindamycin, fluoroquinolones, cephalosporins, and amoxicillin/clavulanate, are associated with
a higher risk of CDI than other antibiotics [48–51].
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Table 5 Time to event-analyses for CLC residents received only one subtype of potentially suboptimal treatment (drug choice, dose
frequency, or excessive treatment duration) as compared to optimal treatment
Outcome

Subtype of potentially
suboptimal treatment

Unadjusted
HR

Lower
95% CI

Upper
95% CI

Adjusted
HR

Lower
95% CI

Upper
95% CI

Poor clinical outcomea

Suboptimal drug choice

0.91

0.86

0.97

0.96

0.91

1.03

Suboptimal dose frequency

1.35

1.25

1.45

1.29

1.20

1.39

Hospitalization/ Emergency
department visitb

c

UTI recurrence

All-cause mortalityd

e

Clostridioides difficile infection

Antibiotic related adverse
drug eventf

Longer than recommended treatment duration

0.92

0.83

1.03

0.90

0.81

1.01

Suboptimal drug choice

0.87

0.80

0.94

0.95

0.87

1.04

Suboptimal dose frequency

1.19

1.07

1.31

1.13

1.02

1.26

Longer than recommended treatment duration

1.08

0.94

1.25

1.03

0.89

1.18

Suboptimal drug choice

0.86

0.78

0.95

0.93

0.84

1.04

Suboptimal dose frequency

1.14

1.01

1.30

1.13

0.99

1.28

Longer than recommended treatment duration

0.88

0.73

1.06

0.85

0.70

1.02

Suboptimal drug choice

1.00

0.89

1.12

0.93

0.82

1.04

Suboptimal dose frequency

1.52

1.33

1.73

1.44

1.26

1.65

Longer than recommended treatment duration

0.68

0.53

0.86

0.71

0.55

0.90

Suboptimal drug choice

0.92

0.67

1.25

1.04

0.75

1.45

Suboptimal dose frequency

3.51

2.66

4.63

3.21

2.42

4.25

Longer than recommended treatment duration

1.64

1.05

2.58

1.37

0.87

2.15

Suboptimal drug choice

0.58

0.25

1.35

0.68

0.29

1.59

Suboptimal dose frequency

1.50

0.65

3.48

1.38

0.59

3.20

Longer than recommended treatment duration

1.21

0.35

4.12

1.20

0.35

4.11

CI Confidence interval, CLC Community Living Center, HR Hazard ratio, UTI Urinary tract infection, VAMC Veterans Affairs Medical Center
a
Adjusted for 8 resident-level covariates (genitourinary disease comorbidity, cardiopulmonary comorbidity, chronic renal disease comorbidity, previous
fluroquinolone exposure in the past 30 days, age, previous VAMC hospitalization in the past 30 days, previous VAMC urine culture in the past 365 days, high white
blood cell count), and 1 CLC-level covariate (total CLC incident UTI rate per 10,000 bed days)
b
Adjusted for 10 resident-level covariates (cardiopulmonary comorbidity, genitourinary disease comorbidity, chronic renal disease comorbidity, age, previous
VAMC hospitalization in the past 30 days, previous outpatient VA urine culture in the past 365 days, previous CLC urine culture in the past 365 days, previous
VAMC urine culture in the past 365 days, high white blood cell count, year of episode) and 1 CLC-level covariate (total CLC incident UTI rate per 10,000 bed days)
c
Adjusted for 5 resident-level covariates (genitourinary disease comorbidity, previous fluroquinolone exposure in the past 30 days, previous fluroquinolone
resistant culture in the past 365 days, previous CLC urine culture in the past 365 days, previous VAMC urine culture in the past 365 days), and 1 CLC-level covariate
(total CLC incident UTI rate per 10,000 bed days)
d
Adjusted for 10 resident-level covariates (history of a skin infection diagnosis in the past 365 days, history of a urinary tract infection diagnosis in the past 365
days, chronic renal disease comorbidity, age, previous fluroquinolone exposure in the past 30 days, previous VAMC hospitalization in the past 30 days, previous
outpatient VA urine culture in the past 365 days, previous VAMC urine culture in the past 365 days, high white blood cell count, year of episode), and 1 CLC-level
covariate (total CLC incident UTI rate per 10,000 bed days)
e
Adjusted for 8 resident-level covariates (history of a skin infection diagnosis in the past 365 days, genitourinary disease comorbidity, chronic renal disease
comorbidity, previous VAMC hospitalization in the past 30 days, previous CLC urine culture in the past 365 days, previous VAMC urine culture in the past 365 days,
high white blood cell count, year of episode), and 1 CLC-level covariate (total CLC incident UTI rate per 10,000 bed days)
f
Adjusted for 2 resident-level covariates (VAMC hospitalization in the past 30 days, year of episode), and 1 CLC-level covariate (total CLC incident UTI rate per
10,000 bed days)

Longer durations of treatment have also been shown to
increase the risk of CDI, potentially through increased
perturbation of the colonic microbiota [52, 53]. Our results are thus likely related to differences in treatment
between residents receiving potentially suboptimal antibiotic treatment and optimal antibiotic treatment, which
is expected as our definition of suboptimal treatment
was based on drug choice, dose frequency, and duration
of treatment. For example, residents who received suboptimal antibiotics were more likely to be treated with
higher risk antibiotics such as fluoroquinolones, some
cephalosporins, amoxicillin/clavulanate, and clindamycin
than those who received optimal antibiotic treatment. In
subgroup analyses, potentially suboptimal antibiotic

treatment was associated with an increased hazard of
CDI in those who initially received monotherapy with
antibiotics known to increase the risk of CDI, including
those initially treated with fluoroquinolones alone and
those treated with cephalosporins alone. Fluoroquinolones may have been more likely to be suboptimal due
to high rates of resistance among urinary isolates in the
VA [54].
Treatment duration was longer among those who received suboptimal antibiotic treatment. A recent longitudinal case-cohort study among residents of nursing
homes in Ontario, Canada found that antibiotic choice
and duration had a significant impact on risk for CDI
[48]. Compared to a 7 day course of antibiotics, a 10-day
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course was associated with a 12% higher risk for CDI
(adjusted relative risk [aRR] 1.12, 95% CI 1.09–1.14) and
a 14 day course was associated with a 27% higher risk
(aRR 1.12, 95% CI 1.21–1.30) [48]. Authors of previous
work did not define whether courses were necessary/unnecessary or optimal/suboptimal, but rather just compared the risk of CDI for any 10- or 14-day course of
antibiotics to any 7-day course. In previous work when
comparing risk of CDI for agents used for 7 days, fluoroquinolone, clindamycin, and cephalosporin agents demonstrated the highest risk for CDI development [48].
However, in our study, suboptimal drug choice and longer than recommended treatment duration were not associated with the composite poor clinical outcome or
CDI. These findings may be related to our definitions of
optimal treatment. As our definition of appropriateness
of drug choice was based on prior susceptibility results
and local antibiograms, it is possible that optimal treatment could of have been overly broad-spectrum coverage to provide sufficient coverage, leading to poor
outcomes and CDI.
The only subtype of potentially suboptimal antibiotic
treatment that was associated with the composite poor
clinical outcome and CDI in our study was potentially
suboptimal dose frequency. The risk of CDI was 2.42
times higher among those treated with a suboptimal
dose frequency versus optimal treatment. Potentially
suboptimal dose frequency was also associated with
hospitalization/ED visits and all-cause mortality. In prior
work, a dose-dependent increased risk of CDI has been
observed, with increasing cumulative defined daily dose
of antibiotics resulting in increasing risks of CDI [55].
Our results suggest that dose frequency, in addition to
drug choice and antibiotic duration, may also impact
risk of CDI and other poor outcomes.
We found no difference in risk for UTI recurrence for
residents treated with potentially suboptimal or optimal
antibiotic treatment. Previous work has found that
among women with UTI, longer courses of antibiotics
may be associated with increased risk of recurrent UTI,
possibly due to alterations in urogenital flora [56–59].
However, among males with UTI treated in the outpatient setting, longer treatment duration was not associated with UTI recurrence, nor was antibiotic choice
[60]. Interestingly, for unclear reasons, among the subgroup of residents treated with initial beta-lactam therapy, suboptimal treatment was associated with a
decreased hazard of UTI recurrence which requires further investigation.
It is possible that suboptimal initial treatment could
lead to clinical failure, the consequences of which could
be serious and may include bacteremia, urosepsis, acute
care hospitalization, and potentially death [23, 61]. In
our study, suboptimal treatment was not associated with
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mortality. It is possible that despite being suboptimal, an
appropriate agent was ultimately used considering the
susceptibility of the uropathogen causing the UTI. Three
previous studies have similarly demonstrated that inappropriate empiric therapy for UTI was not associated
with an increased risk of mortality [62–64]. Excessive
treatment duration versus optimal treatment was associated with a decreased hazard of mortality. The optimal
duration of treatment of males with UTI is largely unknown. In females, durations as short as 3 days are recommended for those with uncomplicated infection, but
for males longer durations between 7 and 14 days are
generally recommended [65–67]. Further investigation is
needed to determine optimal treatment duration in
males to decrease the risk of treatment failure.
We acknowledge the limitations of this retrospective
cohort study. First, our study was not designed to assess
causality, and there are important differences (known
and unknown) between residents who received suboptimal and optimal antibiotic treatment. While we did adjust for confounders of suboptimal treatment and
clinical outcomes, our findings neither confirm nor deny
a causal relationship, as our findings may be confounded
by unmeasured factors which affect suboptimal treatment and clinical outcomes. As such, while we found an
association between suboptimal antibiotic treatment and
poor clinical outcomes even after adjusting for several
resident and CLC characteristics, this association may be
impacted by residual confounding. Second, we defined
UTI based on a urine culture and antibiotic treatment,
per recommendations of the Infectious Diseases Society
of America [65]. While we excluded patients with other
positive cultures and only included those exposed to
common antibiotics recommended by national guidance
or with reliable urinary concentrations, the antibiotic
treatment captured may have been targeting another
non-urinary tract infection type or asymptomatic bacteriuria. Additionally, we did not capture UTIs in which
a urine culture was not obtained. Urine culturing practices are not standardized across VA CLCs, and some facilities may only recommend obtaining UTI cultures in
certain clinical situations, such as recurrent infection.
However, our population was mostly a complicated,
male population, in which urine cultures would be generally recommended. Third, no established definitions
for suboptimal antibiotic treatment of residents with
UTI have been developed. There is no IDSA guidance
for the treatment of complicated UTIs in males, so we
based suboptimal treatment definitions on available
guidelines for uncomplicated infection in females and
expert opinion [65]. Suboptimal antibiotic treatment is
multifactorial and as such we considered three elements
of suboptimal treatment (drug choice, dose frequency,
and longer duration) [25]. However, other elements,
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such as drug strength and route of administration may
also be suboptimal. Insufficient treatment duration is
also a clinical problem. We excluded those treated for 2
days or less, but some residents may have still been exposed to insufficient treatment durations. Future research should continue to investigate and operationalize
the definition of suboptimal antibiotic treatment among
residents with UTI. Additionally, while we conducted
analyses by subtype of suboptimal treatment, comparative analyses are warranted to determine which individual aspects of suboptimal antibiotic treatment (the drug
choice, dose frequency, or longer than recommended
duration) are the most strongly associated with poor
outcomes. Forth, we measured all-cause hospitalizations,
ED visits, and mortality. Our frail older resident population is already at risk for these events and many of the
events observed may have not been related to antibiotic
use. Alternatively, we likely underestimated antibioticrelated adverse events, as these events may not have
been coded or other codes were used. Adverse events
are difficult to identify in large databases as they are
often not recorded in health claims and reports [68].
Fifth, while we investigated five potential harms of suboptimal antibiotic use, we did not assess the development of colonization or infection with resistance, which
is a well-known harm of antibiotic use. Finally, the
generalizability of our findings conducted in a largely
older male population may be limited to other non-VA
long-term care populations.

Conclusions
In this large national study of 19,701 CLC residents
with an incident UTI, suboptimal antibiotic treatment
was associated with increased risk of poor clinical
outcomes. Our results were driven by a 94% increased
risk of CDI with suboptimal use, meaning not unnecessary use, but not the use of the best drug, dose
frequency, and duration. Our work expands on previous work which has found that antibiotic use and unnecessary antibiotic use are associated with a number
of harms in vulnerable older long-term care residents.
Beyond the decision to use antibiotics, clinicians
should consider the potential harms of their antibiotic
choices with regards to drug, dose, and duration, to
ensure that residents are receiving the most optimal
antibiotic treatment. Future research should continue
to investigate the impact of suboptimal treatment
UTI and other common types of infection among
older vulnerable long-term care residents.
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